Targeting glucocorticoid receptor to enhance immunotherapy response in triple negative breast cancer
{{output}}
Background: Immune checkpoint blockade (ICB) therapies for triple negative breast cancer (TNBC) have yielded limited clinical benefits, which may be attributed to the immunosuppressive tumor immune microenvironment (TIME). Glucoc... ...
